A771726, an anti-inflammatory drug, exertsan anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 627-634

  Huang, Ou ^a   Xie, Zuoquan ^b   Zhang, Weili ^c   Lou, Ying ^a   Mao, Yan ^a   Liu, Hongchun ^b   Jiang, Min ^d   Shen, Kunwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c Suzhou Xiangcheng People's Hospital   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

A771726; Apoptosis; Cell cycle; Endocrine resistance; Microarray analysis; Tamoxifen

Indexed keywords

ANTIESTROGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE P60; PROTEIN P53; TAMOXIFEN; TERIFLUNOMIDE; ANILINE DERIVATIVE; ANTIINFLAMMATORY AGENT; CSK TYROSINE-PROTEIN KINASE; HYDROXYBUTYRIC ACID; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTI-INFLAMMATORY AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYBUTYRATES; MCF-7 CELLS; PHOSPHORYLATION; SRC-FAMILY KINASES; TAMOXIFEN;

EID: 84903153240     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3249     Document Type: Article

References (39)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Chlebowski RT, Manson JE, Anderson GL, et al: Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 105: 526-535, 2013.
3. McDonnell DP and Norris JD: Connections and regulation of the human estrogen receptor. Science 296: 1642-1644, 2002. (Pubitemid 34579150)
4. Brouckaert O, Paridaens R, Floris G, Rakha E, Osborne K and Neven P: A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol 24: 47-53, 2013.
5. Pinkerton JV and Thomas S: Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol 142C: 142-154, 2014.
6. Goncalves R, Ma C, Luo J, Suman V and Ellis MJ: Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol 9: 223-229, 2012.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
8. Ali R, Nicholas RS and Muraro PA: Drugs in development for relapsing multiple sclerosis. Drugs 73: 625-650, 2013.
9. Oh J and O'Connor PW: Teriflunomide. Neurol Clin Pract 3: 254-260, 2013.
10. Tallantyre E, Evangelou N and Constantinescu CS: Spotlight on teriflunomide. Int MS J 15: 62-68, 2008.
11. Wiese MD, Rowland A, Polasek TM, Sorich MJ and O'Doherty C: Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol 9: 1025-1035, 2013.
12. Oh J and O'Connor PW: Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs 27: 591-609, 2013.
13. Oh J and O'Connor PW: An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag 9: 177-190, 2013.
14. Zhu S, Yan X, Xiang Z, Ding HF and Cui H: Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. PLoS One 8: e71555, 2013.
15. Hail N Jr, Chen P, Kepa JJ and Bushman LR: Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes. Apoptosis 17: 258-268, 2012.
16. Ringshausen I, Oelsner M, Bogner C, Peschel C and Decker T: The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 22: 635-638, 2008. (Pubitemid 351386736)
17. Hail N Jr, Chen P and Bushman LR: Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia 12: 464-475, 2010.
18. Dietrich S, Krämer OH, Hahn E, et al: Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clin Cancer Res 18: 417-431, 2012.
19. Baumann P, Mandl-Weber S, Völkl A, et al: Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 8: 366-375, 2009.
20. Uckun FM: Rationally designed anti-mitotic agents with proapoptotic activity. Curr Pharm Des 7: 1627-1639, 2001.
21. White RM, Cech J, Ratanasirintrawoot S, et al: DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471: 518-522, 2011.
22. Somnay Y, Chen H and Kunnimalaiyaan M: Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro. Neuroendocrinology 97: 183-192, 2013.
23. Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643, 2009.
24. WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280: 17617-17625, 2005.
25. Abukhdeir AM, Vitolo MI, Argani P, et al: Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA 105: 288-293, 2008.
26. Riggins RB, Bouton AH, Liu MC and Clarke R: Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 71: 201-237, 2005. (Pubitemid 43631307)
27. Razandi M, Pedram A, Jordan VC, Fuqua S and Levin ER: Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 32: 3274-3285, 2013.
28. Martin LA and Dowsett M: BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer? Cancer Cell 24: 7-9, 2013.
29. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC and Clarke R: BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J 24: 2040-2055, 2010.
30. Ning Y, Riggins RB, Mulla JE, Chung H, Zwart A and Clarke R: IFNγ restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-κB, BCL2 family members, and signaling to caspase-dependent apoptosis. Mol Cancer Ther 9: 1274-1285, 2010.
31. Schwartz JL, Shajahan AN and Clarke R: The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer. Int J Breast Cancer 2011: 912102, 2011.
32. Cook KL, Shajahan AN, Wärri A, Jin L, Hilakivi-Clarke LA and Clarke R: Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res 72: 3337-3349, 2012.
33. Geng Y and Sicinski P: Differences in regulation and function of E-cyclins in human cancer cells. Cell Cycle 12: 1165, 2013.
34. Caldon CE, Sergio CM, Kang J, et al: Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 11: 1488-1499, 2012.
35. Miller TW, Balko JM, Fox EM, et al: ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1: 338-351, 2011.
36. Lin JA, Fang SU, Su CL, et al: Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy. Urol Oncol 32: 29.e1-29.e11, 2014.
37. Jiang M, Huang O, Zhang X, et al: Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules 18: 701-720, 2013.
38. Hiscox S, Jordan NJ, Smith C, et al: Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 115: 57-67, 2009.
39. Martinez-Outschoorn UE, Goldberg A, Lin Z, et al: Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12: 924-938, 2011.